

BULLETIN

NO. 55

April 3, 2020

Dear Provider:

Special Authorization Renewal Extensions

For the safety of our beneficiaries and health care providers during the COVID-19 pandemic, and to ensure that our beneficiaries continue to have uninterrupted access to prescribed drugs, the Newfoundland and Labrador Prescription Drug Program will be implementing the following change, effective **April 4, 2020**:

Special Authorization Extensions

- Special authorization approvals for beneficiaries of the NLPDP that were due for renewal between March 1, 2020 and May 31, 2020 will be **extended an additional 6 months from the most recent expiry date**.

This will apply to drugs within the following therapeutic areas:

- DOAC's
- Biologics
- Multiple Sclerosis
- Alzheimer's Disease
- ADHD
- Long Acting Opioid's
- Non-Insulin Anti-Diabetic Drugs
- Certain Pulmonary Drugs (eg for IPF, PAH)
- Long Acting Injectable Anti-Psychotics

- Select drugs are excluded from this process, including drugs with a fixed duration of approval, as outlined in the special authorization criteria (e.g. Hepatitis C drugs).
- This update only applies to special authorization renewals. New requests for drugs that require special authorization approval are not impacted and must be submitted to the NLPDP according to the standard process.

For further assistance, or if you have any questions regarding this change, please call 1-709-729-6507 or our toll-free line at 1-888-222-0533.

ECS200403